NDAORALTABLET, EXTENDED RELEASE
Approved
Mar 2013
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
DESVENLAFAXINE (desvenlafaxine) by Hikma is norepinephrine uptake inhibitors [moa]. First approved in 2013.
Drug data last refreshed 4m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Desvenlafaxine is an oral extended-release SNRI (serotonin-norepinephrine reuptake inhibitor) approved by the FDA in 2013 for major depressive disorder. It works by inhibiting the reuptake of both serotonin and norepinephrine, thereby increasing their availability in the central nervous system. The drug is the active metabolite of venlafaxine, offering an alternative mechanism for patients with depression.
Peak
Product is in peak lifecycle stage under Hikma sponsorship with moderate competitive pressure (30%), suggesting stable but mature market with limited expansion headroom for the brand team.
Mechanism of Action
Norepinephrine Uptake Inhibitors
Pharmacologic Class:
Serotonin and Norepinephrine Reuptake Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study to Evaluate Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Generalized Anxiety Disorder.
Started Jul 2023
555 enrolled
Generalized Anxiety Disorder
Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression
Started Jun 2020
605 enrolled
Major Depressive Disorder
Switching From SSRI to Desvenlafaxine on Cognitive Functioning
Started Apr 2018
36 enrolled
Major Depressive Disorder
Desvenlafaxine for Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen
Started Nov 2017
59 enrolled
Hot FlashesBreast Neoplasms
Desvenlafaxine in Opioid-Dependent Patients
Started Jul 2014
18 enrolled
DepressionOpioid DependenceMethadone Treatment
Worked on DESVENLAFAXINE at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.